XOMA - NASDAQ
XOMA Royalty Corp.
$42.40
+1.7%XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
At a Glance
Live Snapshotxoma
Selling, General and Administrative Expenses
Last Annual Value
36.09M
3-Year CAGR
16%
5-Year CAGR
17%
10-Year CAGR
6%
XOMA Royalty Corp. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
XOMA Royalty Corp. NASDAQ:XOMA | 36.09M | 9.9% | 12.0% | 7.0% | |
 Quantum-Si incorporated NASDAQ:QSI | 44.75M | 0.1% | -2.3% | N/A | |
 Korro Bio, Inc. NASDAQ:KRRO | 28.16M | -8.3% | -4.2% | N/A | |
 4D Molecular Therapeutics, Inc. NASDAQ:FDMT | 49.06M | 10.4% | 11.9% | N/A | |
 MBX Biosciences, Inc. Common Stock NASDAQ:MBX | 18.90M | 40.7% | N/A | N/A | |
 PureTech Health plc NASDAQ:PRTC | 20.65M | -24.7% | -7.7% | -5.7% | |
 RAPT Therapeutics, Inc. NASDAQ:RAPT | 28.88M | 3.5% | 12.5% | N/A | |
 Lineage Cell Therapeutics, Inc. AMEX:LCTX | 18.46M | 2.2% | 0.3% | -4.2% | |
 Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | 86.50M | 5.7% | 15.7% | 24.2% | |
 Aura Biosciences, Inc. NASDAQ:AURA | 22.49M | 4.4% | 17.4% | N/A | |
 Galectin Therapeutics Inc. NASDAQ:GALT | 5.79M | -0.8% | -1.7% | -0.6% |
XOMA Royalty Corp. Fair Value Envelope
Related Guides
Continue your XOMA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.